SG11201907673YA - Pharmaceutical compositions for combination therapy - Google Patents

Pharmaceutical compositions for combination therapy

Info

Publication number
SG11201907673YA
SG11201907673YA SG11201907673YA SG11201907673YA SG11201907673YA SG 11201907673Y A SG11201907673Y A SG 11201907673YA SG 11201907673Y A SG11201907673Y A SG 11201907673YA SG 11201907673Y A SG11201907673Y A SG 11201907673YA SG 11201907673Y A SG11201907673Y A SG 11201907673YA
Authority
SG
Singapore
Prior art keywords
international
pct
rue
bondues
parc
Prior art date
Application number
SG11201907673YA
Inventor
Dean Hum
Robert Walczak
Carole Belanger
Corinne Foucart
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of SG11201907673YA publication Critical patent/SG11201907673YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT omit VIII °nolo omioom 010 01110111110 oimIE (10) International Publication Number WO 2018/167103 Al (51) International Patent Classification: A61K 31/426 (2006.01) A61P 43/00 (2006.01) (21) International Application Number: PCT/EP2018/056310 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305268.9 13 March 2017 (13.03.2017) EP 17190723.1 12 September 2017 (12.09.2017) EP 18305149.9 13 February 2018 (13.02.2018) EP (71) Applicant: GENFIT [FR/FR]; 885 avenue Eugene Avinee, 59120 LOOS (FR). (72) Inventors: HUM, Dean; 38, Parc Saint Georges, 59910 BONDUES (FR). WALCZAK, Robert; Residence Parc d'Isly 13 bis, rue Delezenne, 59000 LILLE (FR). BE- LANGER, Carole; 3 Allee du Verger, 59910 BONDUES (FR). FOUCART, Corinne; 137 rue Saint Victor, 59110 LA MADELEINE (FR). (74) Agent: CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand, 75002 PARIS (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 1-1 KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) 1-1 with sequence listing part of description (Rule 5.2(a)) 1-1 013 1-1 (54) Title: PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY C (57) : The present invention relates to a combination product and its use in therapy.
SG11201907673YA 2017-03-13 2018-03-13 Pharmaceutical compositions for combination therapy SG11201907673YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17305268 2017-03-13
EP17190723 2017-09-12
EP18305149 2018-02-13
PCT/EP2018/056310 WO2018167103A1 (en) 2017-03-13 2018-03-13 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
SG11201907673YA true SG11201907673YA (en) 2019-09-27

Family

ID=61569285

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907673YA SG11201907673YA (en) 2017-03-13 2018-03-13 Pharmaceutical compositions for combination therapy

Country Status (14)

Country Link
US (1) US11191749B2 (en)
EP (1) EP3595656A1 (en)
JP (1) JP2020514352A (en)
KR (1) KR20190122806A (en)
CN (1) CN110430876A (en)
AU (1) AU2018233975A1 (en)
BR (1) BR112019018162A2 (en)
CA (1) CA3054103A1 (en)
IL (1) IL268751B (en)
MX (1) MX2019010322A (en)
PH (1) PH12019501970A1 (en)
SG (1) SG11201907673YA (en)
WO (1) WO2018167103A1 (en)
ZA (1) ZA201906613B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542256B2 (en) 2017-09-03 2023-01-03 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
CA3130713A1 (en) * 2019-04-09 2020-10-15 Peggy Parroche Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
BR112021020496A2 (en) * 2019-04-12 2021-12-07 Genfit Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress
PE20220255A1 (en) 2019-05-08 2022-02-16 Aligos Therapeutics Inc THR MODULATORS AND METHODS OF USING THESE
CN110699308B (en) * 2019-09-20 2021-09-17 华中农业大学 AMH-INH-GNIH three-expression gene vaccine for improving animal fertility, and preparation method and application thereof
CN116942684A (en) * 2020-02-20 2023-10-27 甘莱制药有限公司 Pharmaceutical composition for treating steatohepatitis and preparation method thereof
KR102386097B1 (en) 2020-04-13 2022-04-14 압타바이오 주식회사 composition of pyrazole derivatives for treatment of pulmonary fibrosis
US20230148365A1 (en) 2020-04-13 2023-05-11 Aptabio Therapeutics Inc. Pulmonary fibrosis medicine containing pyrazole derivative
CN113893350B (en) * 2020-07-06 2023-09-15 诺未科技（北京）有限公司 Composition for treating cancer and application and medicine thereof
CN117599188A (en) 2020-07-06 2024-02-27 诺未科技（北京）有限公司 Composition and application thereof in preparation of medicines for treating cancers
US11820754B2 (en) 2020-08-25 2023-11-21 Eli Lilly And Company Polymorphs of an SSAO inhibitor
EP4000616A1 (en) * 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
CN117653737A (en) * 2020-11-30 2024-03-08 诺未科技（北京）有限公司 Composition, application and medicine thereof
JP2024519337A (en) * 2021-05-11 2024-05-10 ジェンフィット Elafibranol derivative agonists of ppar for use in the treatment of sepsis - Patents.com

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4399296A (en) * 1994-12-19 1996-07-10 Lauteral Limited A combination product comprising nitazoxanide and an anti-ulcer agent
TW200416221A (en) 2002-10-30 2004-09-01 Vertex Pharma Compositions useful as inhibitors of ROCK and other protein kinases
AU2007204963B2 (en) * 2006-01-09 2012-09-27 Romark Laboratories, L.C. Viral hepatitis treatment
WO2009023509A2 (en) 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
US20100016262A1 (en) * 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
JP5726766B2 (en) * 2009-02-13 2015-06-03 ロマーク ラボラトリーズ エル．シー． Controlled release pharmaceutical formulation of nitazoxanide
EA201391262A1 (en) * 2011-03-02 2014-03-31 Джером Шентаг COMPOSITION, METHOD OF TREATMENT AND DIAGNOSTICS OF LIVER STEATOSIS AS AN INDEPENDENT DISEASE OR IN COMBINATION WITH HEPATITIS C INFECTION
WO2012162592A1 (en) * 2011-05-25 2012-11-29 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
WO2013082469A2 (en) * 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
US9539139B2 (en) * 2013-05-03 2017-01-10 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
CA2952958A1 (en) * 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
KR20170066418A (en) * 2014-09-12 2017-06-14 토비라 쎄라퓨틱스, 인크. Cenicriviroc combination therapy for the treatment of fibrosis
WO2016123073A1 (en) * 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
JP2019513762A (en) * 2016-04-11 2019-05-30 ジェンフィＧｅｎｆｉｔ Method of treating cholestasis and fibrosis
US10653678B2 (en) * 2016-04-11 2020-05-19 Genfit Methods of treatment for cholestatic and fibrotic diseases
US10905680B2 (en) * 2016-04-11 2021-02-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
EP3442518B1 (en) * 2016-04-11 2024-01-17 Genfit Methods of treatment for cholestatic and fibrotic diseases
ES2928408T3 (en) * 2016-04-11 2022-11-17 Genfit Methods for the treatment of fibrotic diseases

Also Published As

Publication number Publication date
EP3595656A1 (en) 2020-01-22
BR112019018162A2 (en) 2020-04-07
CN110430876A (en) 2019-11-08
CA3054103A1 (en) 2018-09-20
KR20190122806A (en) 2019-10-30
IL268751B (en) 2022-08-01
MX2019010322A (en) 2019-10-21
JP2020514352A (en) 2020-05-21
US20200061028A1 (en) 2020-02-27
IL268751A (en) 2019-10-31
PH12019501970A1 (en) 2020-06-29
US11191749B2 (en) 2021-12-07
ZA201906613B (en) 2020-10-28
WO2018167103A1 (en) 2018-09-20
AU2018233975A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201909168VA (en) Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor
SG11201811432WA (en) Rna for cancer therapy
SG11201809064QA (en) Chimeric neurotoxins
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201901494UA (en) Acid-alpha glucosidase variants and uses thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201810579YA (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201901817SA (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
SG11201808540SA (en) Methods of treatment for cholestatic and fibrotic diseases
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders